Laurus Labs Limited — Capital/Financing Update 2025

Mar 6, 2025

==> picture [190 x 81] intentionally omitted <==

March 06, 2025

ToThe Corporate Relations DepartmentBSE LimitedPhiroze Jeejeebhoy Towers,Dalal Street,Mumbai – 400 001Code: 540222	ToThe Listing DepartmentNational Stock Exchange of India Ltd.,Exchange Plaza,Bandra Kurla Complex, Bandra (E),Mumbai – 400 051Code: LAURUSLABS

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / madam,

With reference to the above, we would like to inform you that the Board of Directors of the Company at their Meeting held today i.e., Thursday, 06[th ] March, 2025, inter-alia, have approved for investment of an amount of INR 833,000,000/- (Indian Rupees Eight Hundred and Thirty Three Million only) in KRKA Pharma Private Limited (“KRKA”), a joint venture of the Company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of INR 867,000,000/- (Indian Rupees Eight Hundred and Sixty Seven Million only) in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs Limited.

The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company’s strategic growth plans and long-term business objectives.

The required details under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed as Annexure-A .

Please take the above information on record.

Yours faithfully,

For Laurus Labs Limited

VENKATESW Digitally signed by VENKATESWAR AR REDDY REDDY GOGIREDDY Date: 2025.03.06 GOGIREDDY 17:01:15 +05'30'

G. Venkateswar Reddy

Company Secretary & Compliance Officer

Encl: A/a

==> picture [453 x 76] intentionally omitted <==

==> picture [190 x 81] intentionally omitted <==

Annexure-A

BRIEF DETAILS OF THE INVESTMENT

(Pursuant to SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024)

a) Name of the target entity, details in brief such as size, turnover etc:

KRKA Pharma Private Limited (“KRKA”), a joint venture of the Company, incorporated under the Companies Act, 2013. The Authorised Share Capital of KRKA is INR 2700,000,000/- divided into 270,000,000 equity shares of INR 10/- each and paid-up Share Capital of the Company is INR 450,000,000/- divided into 45,000,000 equity shares of INR 10/- each.

Turnover: N.A. (Target entity was incorporated on 12.04.2024)

b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”:

Yes. As KRKA Pharma is the joint venture of the Company having common Directors, the proposed investment in KRKA Pharma by the Company would fall within the purview of related party transaction in terms of SEBI (LODR) Regulations, 2015. The nature of interest is to the extent of investment by the Company and the transaction is being done at arms' length basis. No Promoter/ Promoter Group/ other Group Company is holding equity shares in the target entity.

c) Industry to which the entity being acquired belongs:

KRKA Pharma belongs to the pharmaceutical industry.

d) Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):

KRKA Pharma is already a joint venture company of our Company and further investment by the Company and by KRKA d.d., Novo mesto, Slovenia (“co-venturer”) will enable KRKA to acquire land and to meet initial cost of setting up of a manufacturing facility.

e) Brief details of any governmental or regulatory approvals required for the acquisition:

No approvals required.

f) Indicative time period for completion of the acquisition:

The investment by the Company is expected to be completed on or before 31.03.2025.

g) Consideration - whether cash consideration or share swap or any other form and details of the same:

Cash consideration by way of subscribing to Equity Shares which shall be issued by KRKA to the Company.

h) Cost of acquisition and / or the price at which the shares are acquired:

Cost of acquisition: INR 833,000,000/- (Indian Rupees Eight Hundred and Thirty Three Million only) Price at which the shares are acquired: INR 10/- each per equity share

==> picture [453 x 76] intentionally omitted <==

==> picture [190 x 81] intentionally omitted <==

i) Percentage of shareholding / control acquired and / or number of shares acquired:

The current percentage of shareholding in the target entity is 49% and after this investment by our Company and the co-venturer, the percentage of shareholding by the Company shall remain same at 49%. The Company will acquire 83,300,000 equity shares of INR 10/- each.

j) Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):

Brief background: KRKA Pharma was incorporated in 2024 and is yet to commence its business operations.

Date of Incorporation: April 12, 2024

Country in which the acquired entity has presence: N.A.

Turnover for the last three years: N.A.

==> picture [453 x 76] intentionally omitted <==

---